Patent · US Active

Antibody drug conjugates

US10005836B2 · kind B2 · utility

1Cited by

7References

22Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Tinya Abrams · Richmond, US
Steven Bruce Cohen · San Diego, US
Jason Damiano · Oakland, US
Clemens Dürr · Weil am Rhein, DE
Thomas Huber · Basel, CH
Daniel Menezes · Berkeley, US
Kathy Miller · San Francisco, US
Katherine Rendahl · Berkeley, US
Jean-Michel Rene Rondeau · Rixheim, FR

Key dates

Filing date	Nov 13, 2015
Grant date	Jun 26, 2018
Priority date	—
Expiry date	May 4, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/705
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.